Abbott continuous glucose/ketone monitoring and DKA occurrence
What this study tests
Newly registered observational study of Abbott's investigational continuous dual glucose/ketone monitor in 1,200 adults and children with T1D. The study arm describes three months of sensor use while the primary DKA outcome is labelled over 12 months, an unresolved registry ambiguity.
Editorial review: .
Registry checked: 2026-09-17. Registry’s own update: 2026-07-31.
Most recent recorded citation date: 2026-07-31. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence at a glance
- Who can enter the study?
- People aged 2 years or older with T1D diagnosed for at least 12 months who are willing to wear the study sensor; prior use of an Abbott CGM is not required. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- No results posted. The study is expected to start in September 2026, enrol 1,200 participants in New Zealand, and complete in December 2027. The record describes three months of sensor exposure but gives the primary DKA outcome a 12-month time frame; the registry does not yet reconcile those durations.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: Other regions. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- Occurrence of diabetes-related ketoacidosis during 12 months
The full picture
This record has no longer discussion. Use the study criteria, reported results and original sources on this page to assess what is known and what remains unresolved.
Sources
- [1]NCT07739342: Evaluating the occurrence of DKA with Abbott continuous dual glucose/ketone monitoring · Trial registry · 2026-07-31 — NOT_YET_RECRUITING; estimated n=1,200; ages 2+; New Zealand; estimated start September 2026 and completion December 2027. The registry states three months of study-sensor use but a 12-month primary DKA time frame; it does not yet establish that monitoring reduces DKA.